Search | Clinical Trials Finder

Conditions: Focal Seizure, Epilepsy, Focal Epilepsy
Interventions: RAP-219, Placebo; Drug · Other
Lead sponsor: Rapport Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Huntsville, Alabama • Bentonville, Arkansas • Colorado Springs, Colorado + 9 more

Conditions: Psoriasis
Interventions: JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more

Conditions: Osteoarthritis, Knee
Interventions: PF-04457845, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Overland Park, Kansas • San Antonio, Texas

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Neridronic acid 100 mg, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more

Conditions: Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions: Berobenatide, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Bradenton, Florida • Tomball, Texas

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
Interventions: Virtual Statin Management (VSM); Other
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 80 Years
Enrollment: 898 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Adolescent Behaviors
Interventions: Gradebook Game; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 7 Years to 17 Years
Enrollment: 100 participants
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions: Mitapivat, Mitapivat-matching placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 26
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 20 more

Conditions: Stroke
Interventions: GM602, Placebo Comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • Newport Beach, California • Pasadena, California + 5 more

Conditions: Huntington Disease
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 25 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Davis, California • San Diego, California • Englewood, Colorado + 22 more

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions: Pioglitazone, Pioglitazone placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 65 Years to 83 Years
Enrollment: 3,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 34
States / cities: Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more

Conditions: Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions: Varenicline, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: End Stage Renal Disease
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Denver, Colorado • Salt Lake City, Utah

Conditions: Kidney Failure, Chronic
Interventions: Placebo, Genz-644470, Sevelamer carbonate; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 52
States / cities: Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more

Conditions: Primary Biliary Cholangitis
Interventions: Part 1: LJN452, Part 1: Placebo, Part 2: LJN452 Dose level 1, Part 2: Placebo, Part 2: LJN452 Dose level 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Rialto, California • Miami, Florida • Atlanta, Georgia + 6 more

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Stable Coronary Artery Disease
Interventions: Selatogrel, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions: Finerenone, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 28
States / cities: Surprise, Arizona • Stanford, California • Vallejo, California + 22 more

Conditions: Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition; Other · Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Bitopertin, Placebo, SSRI; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more

Search by objective public record fields.

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)

A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.

A Study of TAK-951 in Healthy Adults

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Grade Book Game Evaluation Among 6th Grade Students

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

Effect of Adipokines in Hemodialysis Patients

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)